Biohacker Network
PeptidesEvidence: Early clinical

AOD-9604 Dosage: What the Human Trials Administered

Written by
Daniel Reyes, PhD
Medically reviewed by
Dr. Sarah Lindqvist, MD
Published
June 20, 2025
Updated
June 20, 2025
Last medical review
June 20, 2025
Reviewer scope
Metabolic health
Training session in grayscale — AOD-9604’s human obesity trials tested fat loss and could not convincingly beat placebo

AOD-9604 is the rare research peptide with actual human dosing history: its obesity trials administered oral doses across a wide daily range (studies explored roughly 0.25 mg to 54 mg per day) for up to 12 weeks, establishing tolerability but not sufficient efficacy. Today’s injectable gray-market use ignores both facts — the trials were oral, and they failed. No dose is FDA-endorsed for anything.

What the trials actually did

The clinical program tested once-daily oral tablets across multiple dose arms for 12-week periods. Two findings survived: tolerability was good across the range, and no dose achieved weight loss worth approving. A wide flat dose-response curve is itself evidence — usually of a weak effect.

Oral capsules on a blue surface — AOD-9604’s human trials were once-daily oral tablets, not the injectables sold today

The route bait-and-switch

Modern sellers ship AOD-9604 as an injectable, citing trial safety generated with oral tablets. Route changes pharmacokinetics entirely; the trial record does not transfer. Injectable AOD-9604 has essentially no published human data of its own.

The full development story is in our AOD-9604 guide. Contrast this record with semaglutide’s trial evidence, and see how forum dosing culture works in the BPC-157 dosage research. Baseline your actual energy balance with the TDEE calculator.

Our position

This page reports what published studies and regulatory documents describe. It never recommends a dose — dosing is a clinical decision for a licensed prescriber who knows your history. With approved, strongly evidenced metabolic medications now available by prescription, the honest comparison is not flattering to a compound that failed its own program.

Frequently asked questions

What doses did AOD-9604 human trials use?
The clinical program tested once-daily oral tablets across a wide range — studies explored roughly 0.25 mg to 54 mg per day — for up to 12 weeks. Tolerability was good across the range; efficacy was not sufficient at any dose.
Is injectable AOD-9604 supported by the trials?
No. The human safety record was generated with oral tablets; modern sellers ship injectables citing that record. Route changes pharmacokinetics entirely, and injectable AOD-9604 has essentially no published human data of its own.
Was AOD-9604 safe in its trials?
The oral trials reported genuinely decent tolerability — one of the better safety records among research peptides. Safety without efficacy is why the program ended, and why marketing it as a proven fat-burner contradicts its own history.

Questions to ask a licensed clinician

  • Why would I use a failed oral compound by injection instead of evidence-based options?

References

  1. Heffernan M, Summers RJ, Thorburn A, et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology / metabolic research program. SourcePreclinical
  2. US Food and Drug Administration (2023). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA Human Drug Compounding. SourceAgency notice

Related tools

Related guides

Something incorrect in this guide? Report a correction. Material corrections are noted on the page with the date and nature of the change.